Landmark trial
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial
de Boer SM, Powell ME, Mileshkin L, et al. · PORTEC Study Group
DoseLab summary
PORTEC-3 compared pelvic radiotherapy alone with chemoradiotherapy followed by adjuvant chemotherapy for high-risk endometrial cancer. Open access. Citation checked against Europe PMC.
Why this is useful
The trial behind pelvic chemoradiation for high-risk endometrial cancer.
Reference details
- Title
- Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial
- Authors / organization
- de Boer SM, Powell ME, Mileshkin L, et al. · PORTEC Study Group
- Publication / protocol
- Lancet Oncol. 2018;19(3):295–309
- Version
- Pending verification
- Year
- 2018
- DOI
- 10.1016/S1470-2045(18)30079-2
- Disease sites
- GYN
- Topics
- Endometrium, Post-operative, Chemoradiation
- Fractionation context
- Pending verification
- Last reviewed by DoseLab
- Pending verification